TNF单抗-话题@MedSci

[GetTopicListResponse(id=1795767, encodeId=e3f01e9576742, content=<a href='/topic/show?id=7f1e1e5992d' target=_blank style='color:#2F92EE;'>#TNF单抗#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=27, createdTime=2021-07-19, rootId=0, userName=anan, userId=236b481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795766, encodeId=77321e9576624, content=<a href='/topic/show?id=7f1e1e5992d' target=_blank style='color:#2F92EE;'>#TNF单抗#</a>, objectTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, objectType=article, longId=186376, objectId=0af51863e634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af51863e634, replyNumber=0, likeNumber=36, createdTime=2020-09-06, rootId=0, userName=anan, userId=236b481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af51863e634, moduleTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af51863e634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795764, encodeId=1c2c1e95764cf, content=<a href='/topic/show?id=7f1e1e5992d' target=_blank style='color:#2F92EE;'>#TNF单抗#</a>, objectTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, objectType=article, longId=178540, objectId=b7281e8540c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7281e8540c0, replyNumber=0, likeNumber=36, createdTime=2020-03-16, rootId=0, userName=anan, userId=236b481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7281e8540c0, moduleTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7281e8540c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795765, encodeId=c24f1e95765d5, content=<a href='/topic/show?id=7f1e1e5992d' target=_blank style='color:#2F92EE;'>#TNF单抗#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=27, createdTime=2020-10-11, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795763, encodeId=46491e957633f, content=<a href='/topic/show?id=7f1e1e5992d' target=_blank style='color:#2F92EE;'>#TNF单抗#</a>, objectTitle=美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应, objectType=article, longId=162064, objectId=ec44162064e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec44162064e5, replyNumber=0, likeNumber=32, createdTime=2019-06-27, rootId=0, userName=anan, userId=236b481, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec44162064e5, moduleTitle=美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec44162064e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TNF单抗

2020-05-29

anan (审核中...)

前往app查看评论内容

#TNF单抗#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2021-07-19

anan (审核中...)

前往app查看评论内容

#TNF单抗#

UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎

2020-09-06

anan (审核中...)

前往app查看评论内容

#TNF单抗#

信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当

2020-03-16

柳叶一刀 (审核中...)

前往app查看评论内容

#TNF单抗#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2020-10-11

anan (审核中...)

前往app查看评论内容

#TNF单抗#

美国皮肤病学会（AAD）年会发布，TNF单抗Certolizumab治疗斑块型银屑病可实现2年的持久性应答反应

2019-06-27

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#TNF单抗#

科室

工具

服务